Abstract
Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Current Cancer Therapy Reviews
Title:Pathology of the HPV-associated Oropharyngeal Carcinoma
Volume: 11 Issue: 1
Author(s): Yuki Fukumura
Affiliation:
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Abstract: Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Export Options
About this article
Cite this article as:
Fukumura Yuki, Pathology of the HPV-associated Oropharyngeal Carcinoma, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573394711666150428003428
DOI https://dx.doi.org/10.2174/1573394711666150428003428 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Diabetic Retinopathy: Role of Oxidative Stress
Current Drug Targets Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry The Effects of All-Trans-Retinoic Acid on Cell Cycle and Alkaline Phosphatase Activity in Pancreatic Cancer Cells
Medicinal Chemistry The Nature of Enzymes Involved in Uracil-DNA Repair: Isoform Charac-teristics of Proteins Responsible for Nuclear and Mitochondrial Genomic Integrity 1
Current Protein & Peptide Science Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design PEDF in Angiogenic Eye Diseases
Current Molecular Medicine The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry